Blog - Page 16 of 5383 - QualityStocks

ThursdayJun 05, 2025 11:15 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics. HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25. Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer. NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical…

ThursdayJun 05, 2025 10:30 am

Nightfood Holdings Inc. (NGTF) Taps Proven Leaders to Accelerate Hospitality Innovation

Nightfood Holdings new executives have strong track records in a variety of spaces NGTF's new leadership team is poised to leverage their combined expertise to facilitate the company's growth and innovation The foundation of any successful company often rests on the quality and vision of its leadership. Experienced executives can be the deciding factor between stagnation and rapid growth, particularly in dynamic sectors such as consumer goods and hospitality. That’s why Nightfood Holdings (OTCQB: NGTF) made waves recently with its announcement of new senior leadership appointments aimed at accelerating innovation and expansion across its growing portfolio of hospitality-focused services. According…

ThursdayJun 05, 2025 10:00 am

QualityStocksNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell

Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has received regulatory clearance under Italy’s Golden Power regulation to proceed with its option to acquire 100% of Pincell S.r.l., an Italian biotech company. The approval, issued by Italy’s Coordination Group and Ministry of Health, supports Scinai’s strategic move to expand its inflammation and immunology pipeline. Pincell’s lead asset, PC111—a monoclonal antibody targeting the Fas/FasL pathway—holds Orphan Drug Designation in Pemphigus and is being developed for severe skin disorders. The acquisition remains subject to final conditions, including a €12 million grant decision expected later this summer. To view the full press release, visit https://ibn.fm/qoRQ1…

ThursdayJun 05, 2025 9:50 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled "The Future and Promise of TPI 287," will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma patients, including 3 complete and 9 partial responses in a Phase 1 trial. TPI 287, which has FDA Orphan Drug Designation for gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, may offer a breakthrough in treating CNS tumors by effectively crossing the blood-brain barrier. To view…

ThursdayJun 05, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Buprenorphine is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder and chronic and severe pain Nutriband is developing a novel transdermal delivery system for buprenorphine, projected to reach peak annual sales of $70M - $130M The company’s AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected…

ThursdayJun 05, 2025 9:30 am

QualityStocksNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Reports Promising Copper Targets at Epworth Project in Nunavut

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF) has released results from its 2024 exploration program at the Epworth Project in Nunavut, highlighting surface samples with copper grades up to 61.2% and silver up to 5,600 g/t. The company’s MobileMT airborne geophysical survey identified extensive conductive bodies—interpreted as potential reductants such as pyrite or graphite—within the Proterozoic Recluse Group rocks. CEO Thomas Ullrich stated these findings support the potential for a large-scale, sediment-hosted copper system, drawing parallels to successful models used in Central Africa and Aston Bay’s Storm Copper Project. Targets span tens of kilometers and are largely within 300 meters of…

ThursdayJun 05, 2025 9:20 am

QualityStocksNewsBreaks – SolarBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) to Allocate Solar Project Revenue to Bitcoin Treasury Strategy

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has taken its first step toward implementing a Bitcoin treasury strategy by committing net revenue from its 3.79 MW Geddes Solar Power Project to Bitcoin purchases. This initiative places SolarBank among the early renewable energy companies integrating digital assets into corporate finance. The Geddes Project, built on a repurposed landfill, is expected to begin operations by the end of June 2025. CEO Dr. Richard Lu described the move as a strategic blend of stable energy cash flow and Bitcoin’s appreciation potential, with future expansions of the…

ThursdayJun 05, 2025 9:00 am

QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Featured in Editorial Highlighting Next Wave of Scalable Gold Producers

ESGold (CSE: ESAU) (OTCQB: ESAUF) today announced its inclusion in a NetworkNewsWire (“NNW”) editorial spotlighting the emerging class of near-term gold producers positioned for institutional interest. As gold prices climbed above $3,000 per ounce in May 2025, investor demand has shifted toward companies offering leverage, scalability and recurring revenue—traits ESGold is designed to deliver. With a clean balance sheet and scalable model, ESGold is gaining attention as central banks increase gold reserves and institutional capital seeks stronger exposure to the metal’s long-term upside. To view the full press release, visit https://ibn.fm/vbgsS About ESGold Corp. ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D) is…

ThursdayJun 05, 2025 9:00 am

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) Is ‘One to Watch’

Fiscal 2025 marked record revenues of nearly $299 million, with silver production of 6.9 million ounces and 11% year-over-year growth in silver equivalent output. The company maintains industry-leading margins with an all-in sustaining cost of $12.12 per ounce of silver over the last 12 months, reinforcing its position as a low-cost producer. The company maintains a strong balance sheet with over $369 million in cash and a strategic equity portfolio, ensuring financial flexibility for future growth. The company launched construction of its fully funded El Domo copper-gold mine in 2025, with production expected by the end of 2026. Silvercorp has…

WednesdayJun 04, 2025 3:36 pm

QualityStocksNewsBreaks – Adageis Empowers Providers with Actionable Insights for Value-Based Care Success

Adageis, a growing healthcare technology company, offers a unique streamlined and AI-powered software solution designed to make the shift toward value-based care simpler for healthcare practices. “At the core of the company’s offering is the ProActive Care Platform, a patented, AI-centric engine that enables providers, health systems, ACOs, and CINs to identify and act on high-value opportunities within their existing operations,” reads a recent article. “What sets Adageis apart is ease of use, giving practices clear, actionable insights on where value lies, and how to pursue it while maintaining or improving quality of care.” To view the full article, visit…

Site Search

Company Search